



NCCTG

NORTH CENTRAL CANCER TREATMENT GROUP

Date: February 18, 2011

To: Primary Clinical Research Associates

From: Sara Braun
Research Protocol Specialist

Re: N0871, A Phase II Study of Carboplatin (CBDCA), Paclitaxel (TAXOL), and Everolimus (RAD001) in Previously Untreated Patients with Measurable Disease with Cancer of Unknown Primary (CUP)

The following form has been revised as follows:

CRF Title	Brief Description of Edit
Reimbursement Request Form	<ul style="list-style-type: none"><li data-bbox="824 907 1370 1003">• The third column heading now reads “Max \$ allowed per item procedure or test completed.”<li data-bbox="824 1012 1370 1100">• The maximum number of patients for the Lipid panel has been changed to 3 no max.

If you have any questions, please feel free to contact me at 507/538-8226.

SB
Enclosure